Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Turning Point Therapeutics, Inc. | tptx-10k_20201231.htm |
| EX-31.1 - EX-31.1 - Turning Point Therapeutics, Inc. | tptx-ex311_9.htm |
| EX-31.2 - EX-31.2 - Turning Point Therapeutics, Inc. | tptx-ex312_11.htm |
| EX-32.1 - EX-32.1 - Turning Point Therapeutics, Inc. | tptx-ex321_8.htm |
| EX-10.20 - EX-10.20 - Turning Point Therapeutics, Inc. | tptx-ex1020_194.htm |
| EX-23.1 - EX-23.1 - Turning Point Therapeutics, Inc. | tptx-ex231_14.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Turning Point Therapeutics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that::
|
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
|
|
By: |
|
/s/ Yi Larson |
|
|
|
|
|
|
Yi Larson |
|
|
|
|
|
Executive Vice President and Chief Financial Officer (Principal Financial Officer) |